These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 29373227)
1. Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. Tanahashi N; Yamaguchi T; Awano H; Matsuda H J Stroke Cerebrovasc Dis; 2018 May; 27(5):1302-1310. PubMed ID: 29373227 [TBL] [Abstract][Full Text] [Related]
2. Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). Yamaguchi T; Awano H; Matsuda H; Tanahashi N; J Stroke Cerebrovasc Dis; 2017 Apr; 26(4):756-765. PubMed ID: 27887792 [TBL] [Abstract][Full Text] [Related]
3. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462 [TBL] [Abstract][Full Text] [Related]
4. Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase. Tsuruoka A; Atsumi C; Mizukami H; Imai T; Hagiwara Y; Hasegawa Y J Stroke Cerebrovasc Dis; 2014; 23(10):2894-2899. PubMed ID: 25282183 [TBL] [Abstract][Full Text] [Related]
6. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator. Ong CT; Wong YS; Wu CS; Su YH Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721 [TBL] [Abstract][Full Text] [Related]
7. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341 [TBL] [Abstract][Full Text] [Related]
8. Impact of Tissue Plasminogen Activator Dosing on Patients Weighing More Than 100 kg on 3-Month Outcomes in Acute Ischemic Stroke. Garavaglia J; Sherman J; Yetzer H; Regier M; Smith M J Stroke Cerebrovasc Dis; 2017 May; 26(5):1041-1046. PubMed ID: 28129994 [TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry. Kamouchi M; Sakai H; Kiyohara Y; Minematsu K; Hayashi K; Kitazono T J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):e470-6. PubMed ID: 23800495 [TBL] [Abstract][Full Text] [Related]
10. Very Early versus Delayed Rehabilitation for Acute Ischemic Stroke Patients with Intravenous Recombinant Tissue Plasminogen Activator: A Nationwide Retrospective Cohort Study. Momosaki R; Yasunaga H; Kakuda W; Matsui H; Fushimi K; Abo M Cerebrovasc Dis; 2016; 42(1-2):41-8. PubMed ID: 26986718 [TBL] [Abstract][Full Text] [Related]
11. Correlation of Changes in Leukocytes Levels 24 Hours after Intravenous Thrombolysis With Prognosis in Patients With Acute Ischemic Stroke. Chen J; Zhang Z; Chen L; Feng X; Hu W; Ge W; Li X; Jin P; Shao B J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2857-2862. PubMed ID: 30064868 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous administration of recombinant tissue plasminogen activator and edaravone in acute cerebral ischemic stroke patients. Takenaka K; Kato M; Yamauti K; Hayashi K J Stroke Cerebrovasc Dis; 2014; 23(10):2748-2752. PubMed ID: 25307430 [TBL] [Abstract][Full Text] [Related]
13. Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator. Wada T; Yasunaga H; Inokuchi R; Horiguchi H; Fushimi K; Matsubara T; Nakajima S; Yahagi N J Neurol Sci; 2014 Oct; 345(1-2):106-11. PubMed ID: 25085762 [TBL] [Abstract][Full Text] [Related]
14. Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger. Baba H; Sugimori H; Nanishi E; Nagata H; Lee S; Kuwashiro T; Hashizume M J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):903.e5-8. PubMed ID: 21421331 [TBL] [Abstract][Full Text] [Related]
15. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study. Aoki S; Hosomi N; Sueda Y; Kono T; Takamatsu K; Ohyama H; Torii T; Kitamura T; Nomura E; Noda K; Ohtsuki T; Matsumoto M; J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2747-53. PubMed ID: 26360972 [TBL] [Abstract][Full Text] [Related]